Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Arcellx Inc (ACLX)

Arcellx Inc (ACLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 765,080
  • Shares Outstanding, K 43,819
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,970 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.45
Trade ACLX with:

Options Overview Details

View History
  • Implied Volatility 108.00% ( -7.75%)
  • Historical Volatility 60.72%
  • IV Percentile 12%
  • IV Rank 30.10%
  • IV High 130.77% on 08/26/22
  • IV Low 98.19% on 08/15/22
  • Put/Call Vol Ratio 0.20
  • Today's Volume 6
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 449
  • Open Int (30-Day) 356

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.88
  • Number of Estimates 3
  • High Estimate -0.71
  • Low Estimate -1.01
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.63 +11.71%
on 08/29/22
21.15 -17.45%
on 09/15/22
-0.52 (-2.89%)
since 08/23/22
3-Month
15.63 +11.71%
on 08/29/22
23.49 -25.67%
on 08/01/22
+0.65 (+3.87%)
since 06/23/22

Most Recent Stories

More News
Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet

The mean of analysts' price targets for Arcellx, Inc. (ACLX) points to a 61.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

ACLX : 17.46 (-1.41%)
Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference

/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...

ACLX : 17.46 (-1.41%)
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results

/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...

ACLX : 17.46 (-1.41%)
Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...

ACLX : 17.46 (-1.41%)
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...

ACLX : 17.46 (-1.41%)
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering

/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...

ACLX : 17.46 (-1.41%)
ASCO 2022: Surprising News in Cancer Research

The American Society of Clinical Oncology (ASCO) just finished up its annual meeting. We have some winners coming out of the conference.

ADPT : 6.50 (-5.80%)
LGND : 81.12 (-0.47%)
ACLX : 17.46 (-1.41%)
Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

GAITHERSBURG, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the...

ACLX : 17.46 (-1.41%)
Arcellx Announces Pricing of Initial Public Offering

GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the...

ACLX : 17.46 (-1.41%)

Business Summary

Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 18.62
2nd Resistance Point 18.10
1st Resistance Point 17.78
Last Price 17.46
1st Support Level 16.93
2nd Support Level 16.41
3rd Support Level 16.09

See More

52-Week High 26.91
Fibonacci 61.8% 18.94
Last Price 17.46
Fibonacci 50% 16.47
Fibonacci 38.2% 14.01
52-Week Low 6.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar